ロード中...

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab

In selected patients with moderate to severe active ulcerative colitis who have failed to respond or are poorly responsive to standard pharmacologic forms of treatment with corticosteroids and immunosuppressive agents, therapy with a biological agent may be considered. While infliximab is an establi...

詳細記述

保存先:
書誌詳細
第一著者: Freeman, Hugh J
フォーマット: Artigo
言語:Inglês
出版事項: Dove Medical Press 2013
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3826758/
https://ncbi.nlm.nih.gov/pubmed/24235838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S38852
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!